# Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

> **NCT04730232** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 63 (estimated)

## Conditions studied

- High-Risk
- Non-Muscle Invasive Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT04730232
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-27
- **Primary completion:** 2024-02
- **Final completion:** 2024-07
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730232, "Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04730232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*